MW 368.4 Da. High purity flavonoid derivative. Potent antioxidant, anti-inflammatory, analgesic and anticancer agent. Lipooxygenase and cyclooxygenase inhibitor (IC50 values are 8 and 52 μM, respectively). Shows diverse range of actions including free radical scavenging activity, cardio and neuroprotective effects. Blood brain barrier permeable. Active in vitro and in vivo.
458-37-7
Solid
368.4 Da
C21H20O6
969516
Synthetic
1,8-cineole 2-exo-monooxygenase, 17-beta-HSD 2, 17-beta-hydroxysteroid dehydrogenase type 2, 20-alpha-HSD, 20-alpha-hydroxysteroid dehydrogenase, 28 kDa heat shock protein, A BETA, A4 amyloid protein, A4_HUMAN, AAA, ABPP, ACLS, AD1, AHD2, AI838772, AICD-50, AICD-57, AICD-59, AID(50), AID(57), AID(59), AIS, AL1A1_HUMAN, ALDC, ALDH 1, ALDH 11, ALDH class 1, ALDH, liver cytosolic, ALDH-E1, ALHDII, ANDR_HUMAN, AOFA_HUMAN, AOFB_HUMAN, APP, APPI, AR, AR8, ARO, ARO1, AU043990, AW493413, AW743335, Acetaldehyde dehydrogenase 1, Adrenalin oxidase, Albendazole monooxygenase, Albendazole sulfoxidase, Aldehyde dehydrogenase, Aldehyde dehydrogenase 1 family member A1, Aldehyde dehydrogenase 1 soluble, Aldehyde dehydrogenase 1A1, Aldehyde dehydrogenase cytosolic, Aldehyde dehydrogenase family 1 member A1, Aldehyde dehydrogenase liver cytosolic, Alpha-PAK, Alzheimer disease amyloid protein, Amine oxidase (flavin containing), Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B, Amyloid beta (A4) precursor protein, Amyloid beta A4 protein, Amyloid beta protein, Amyloid intracellular domain 50, Amyloid intracellular domain 57, Amyloid intracellular domain 59, Amyloid precursor protein, Androgen nuclear receptor variant 2, Androgen receptor, Androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease), Antigen NY-CO-13, Aromatase, Atherosclerosis, susceptibility to, included, Avian erythroblastic leukemia viral (v erb b) oncogene homolog, BAZ2B_HUMAN, BCC7, BXR, Beta-APP40, Beta-APP42, Beta-amyloid precursor protein, Bromodomain adjacent to zinc finger domain 2B, Bromodomain adjacent to zinc finger domain protein 2B, C10orf70, C31, CAR, CAR BETA, CARA, CBP_HUMAN, CD142, CD142 antigen, CDGSH iron sulfur domain 1, CDGSH iron-sulfur domain-containing protein 1, CISD1_HUMAN, CMT2F, CP19A_HUMAN, CP33, CP34, CP3A4_HUMAN, CPV1, CREB-binding protein, CTFgamma, CVAP, CYAR, CYP19, CYP3, CYP3A, CYP3A3, CYP3A4, CYPIIIA3, CYPIIIA4, CYPXIX, Car 1, Cell growth inhibiting protein 40, Cell proliferation inducing protein 61, Cellular tumor antigen p53, Cerebral vascular amyloid peptide, Coagulation factor III, Coagulation factor III (thromboplastin tissue factor), Constitutive activator of retinoid response, Constitutive active response, Constitutive androstane receptor, Cyclic AMP responsive enhancer binding protein, Cyp19a1, Cytochrome P-450AROM, Cytochrome P450 19A1, Cytochrome P450 3A3, Cytochrome P450 3A4, Cytochrome P450 HLp, Cytochrome P450 NF-25, Cytochrome P450 family 3 subfamily A polypeptide 4, Cytochrome P450 subfamily IIIA polypeptide 4, Cytochrome P450, family 19, subfamily A, polypeptide 1, Cytochrome P450, subfamily XIX (aromatization of androgens), Cytochrome P450-PCN1, D10Ertd214e, DHB2_HUMAN, DHTR, DKFZp434H071, DKFZp586P1322, DKFZp686N23123, DKFZp762I0516, DNA binding protein, DNA replication inhibitor, Dihydro testosterone receptor, Dihydrotestosterone receptor (DHTR), E2DH, EC 1.4.3.4, EDH17B2, EGFR_HUMAN, ER, ER-alpha, ER-beta, ERBB, ERBB1, ERK-2, ERR a, ERR-alpha, ERR1 protein, ERR1_HUMAN, ERT1, ER[a], ER[b], ESR, ESR B, ESR BETA, ESR1_HUMAN, ESRA, ESRL 1, ESRR A, ESTR B, Eag-related protein 1, Epidermal growth factor receptor, Epidermal growth factor receptor (avian erythroblastic leukemia viral (v erb b) oncogene homolog), Epidermal growth factor receptor (erythroblastic leukemia viral (v erb b) oncogene homolog avian), Era, Erb, Erb2, Errp, Estr, Estra, Estradiol 17-beta-dehydrogenase 2, Estradiol Receptor alpha, Estradiol Receptor beta, Estradiol receptor, Estrogen Receptor 1, Estrogen Receptor 2, Estrogen receptor, Estrogen receptor 1 (alpha), Estrogen receptor 2 (ER beta), Estrogen receptor 2 ER beta, Estrogen receptor alpha, Estrogen receptor beta 4, Estrogen receptor related 1, Estrogen receptor-like 1, Estrogen resistance, included, Estrogen synthase, Estrogen synthetase, Estrogen-regulated 24 kDa protein, Estrogen-related receptor alpha, Estrra, Ether a go go related potassium channel protein, Ether-a-go-go-related gene potassium channel 1, Ether-a-go-go-related protein 1, Extracellular signal-regulated kinase 2, F3, FLJ11090, FLJ17960, FLJ45644, FLJ92943, GCCR, GCPS, GCRST, GCR_HUMAN, GEMI_HUMAN, GLI Kruppel family member GLI 3, GLI Kruppel family member GLI3 (Greig cephalopolysyndactyly syndrome), GLI family zinc finger 3, GLI3 C-terminally truncated form, GLI3 form of 190 kDa, GLI3 form of 83 kDa, GLI3 full length protein, GLI3-190, GLI3-83, GLI3FL, GLI3_HUMAN, GMNN, GR, GSK-3 beta, GSK3B_HUMAN, GSK3beta isoform, Gamma-CTF(50), Gamma-CTF(57), Gamma-CTF(59), Geminin, Geminin DNA replication inhibitor, Glioma associated oncogene family zinc finger 3, Glucocorticoid inducible P450, Glucocorticoid receptor, Glutathione S transferase 1 like 1, Glycogen synthase kinase-3 beta, Grl1, H-ERG, HDL cholesterol, augmented response of, to hormone replacement, included, HEL-S-102, HEL-S-53e, HER1, HLP, HMN2B, HS.76067, HSD17, HSP 27, HSPB1_HUMAN, HUMARA, HYSP1, Heat Shock Protein 27, Heat shock 25kDa protein 1, Heat shock 27 kDa protein, Heat shock 27kD protein 1, Heat shock 27kDa protein 1, Heat shock 28kDa protein 1, Heat shock protein beta-1, Hsp 25, Hsp 28, Hydroxysteroid (17 beta) dehydrogenase 2, KAT3A, KCNH2_HUMAN, KD, Kennedy disease (KD), Kv11.1, LFS1, LQT 2, MAO, brain, MAO, platelet, MAO-A, MAO-B, MAP kinase 1, MAP kinase 2, MAP kinase isoform p42, MAPK 1, MB67, MDS029, MGC10317, MGC104252, MGC104309, MGC112732, MGC126680, MGC130000, MGC130001, MGC14684, MGC2318, MGC26382, MGC97144, MGST-IV, MGST1 like 1, MGST1-L1, MK01_HUMAN, MPGES, Microsomal 17-beta-hydroxysteroid dehydrogenase, Microsomal glutathione S-transferase 1-like 1, Microsomal monooxygenase, Microsomal prostaglandin E synthase 1, MitoNEET, Mitogen-activated protein kinase 1, Mitogen-activated protein kinase 2, Monoamine oxidase A, Monoamine oxidase B, Monoamine oxidase type A, Monoamine oxidase type B, Mutant tumor protein 53, Myocardial infarction, susceptibility to, included, NF 25, NISBD2, NR1B1, NR1C3, NR1I2_HUMAN, NR1I3_HUMAN, NR3A1, NR3A2, NR3B1, NR3C4, Nifedipine oxidase, Nuclear mitotic apparatus protein retinoic acid receptor alpha fusion protein, Nuclear receptor subfamily 1 group B member 1, Nuclear receptor subfamily 1 group C member 3, Nuclear receptor subfamily 1 group I member 2, Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 3 group A member 1, Nuclear receptor subfamily 3 group A member 2, Nuclear receptor subfamily 3 group B member 1, Nuclear receptor subfamily 3 group C member 1, Nuclear receptor subfamily 3 group C member 4, Nuclear receptor subfamily 3 group C member 4 (NR3C4), Nucleophosmin retinoic acid receptor alpha fusion protein NPM RAR long form, ONR 1, OTTHUMP00000017718, OTTHUMP00000017719, OTTHUMP00000023166, OTTHUMP00000039393, OTTHUMP00000162543, OTTHUMP00000162897, OTTHUMP00000162898, OTTHUMP00000198350, OTTHUMP00000215173, OTTHUMP00000215174, OTTHUMP00000215175, Oncogen ERBB, Oncogene GLI3, Orphan nuclear receptor MB67, Orphan nuclear receptor NR1I3, Orphan nuclear receptor PAR 1, Orphan nuclear receptor PXR, P 450AROM, P21 protein (Cdc42/Rac) activated kinase 1, P21/Cdc42/Rac1 activated kinase 1 (yeast Ste20 related), P38, P41, P450 III steroid inducible, P450 PCN1, P450, family III, P450C3, P53_HUMAN, P68-PAK, PAK alpha, PAK1_HUMAN, PAP A, PAPB, PAR, PAR q, PGES, PIG 12, PIG61, PN 2, PN-II, PP 102, PP 1294, PPAR-gamma, PPARG2, PPARG_HUMAN, PPD IV, PRKM 2, PRKM1, PRR, PTGES_HUMAN, PUMB 1, Paka, Peroxisome proliferator activated receptor gamma 2, Peroxisome proliferator-activated receptor gamma, Phosphoprotein p53, Potassium channel HERG, Potassium voltage gated channel subfamily H (eag related) member 2, Potassium voltage-gated channel subfamily H member 2, PreA4, Pregnane X receptor, Prostaglandin E synthase, Protease nexin-II, Protein kinase MUK2, Proto-oncogene c-ErbB-1, Quinine 3-monooxygenase, RALDH 1, RAR, RAR-alpha, RARA_HUMAN, RARalpha1, RGD1309529, RNESTROR, RP24-311F12.2, RP3 369A17.3, RSTS, RTS, Rac/p21-activated kinase, Receptor tyrosine-protein kinase ErbB-1, Retinal dehydrogenase 1, Retinoic acid nuclear receptor alpha variant 1, Retinoic acid nuclear receptor alpha variant 2, Retinoic acid receptor alpha, Retinoic acid receptor alpha polypeptide, Rubinstein Taybi syndrome, S-APP-alpha, S-APP-beta, SA7, SBMA, SCAN1, SDR9C2, SMAX1, SQT1, SRP27, STE20 homolog yeast, SXR, Serine/threonine-protein kinase GSK3B, Serine/threonine-protein kinase PAK 1, Short chain dehydrogenase/reductase family 9C, member 2, Species antigen 7, Spinal and bulbar muscular atrophy, Spinal and bulbar muscular atrophy (SBMA), Steroid and xenobiotic receptor, Steroid hormone receptor ERR1, Stress-responsive protein 27, TFA, TFM, TF_HUMAN, TP53I12, TRP53, TYDP, TYDP1_HUMAN, Taurochenodeoxycholate 6-alpha-hydroxylase, Testicular Feminization (TFM), Testosterone 17-beta-dehydrogenase, Thromboplastin, Tissue factor, Tp53, Transcriptional activator GLI3, Transcriptional repressor GLI3R, Transformation related protein 53, Tumor protein 53, Tumor protein p53, Tumor protein p53 inducible protein 12, Tumor suppressor p53, Tyr-DNA phosphodiesterase 1, Tyramine oxidase, Tyrosyl-DNA phosphodiesterase 1, Urogastrone, Voltage gated potassium channel, subfamily H, member 2, Voltage-gated potassium channel subunit Kv11.1, WALp4, Wa5, ZCD1, Zinc finger CDGSH type domain 1, Zinc finger protein GLI 3, androgen receptor splice variant 4b, beta-amyloid peptide, constitutive active receptor, constitutive androstane nuclear receptor variant 2, constitutive androstane nuclear receptor variant 3, constitutive androstane nuclear receptor variant 4, constitutive androstane nuclear receptor variant 5, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 3, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 4, cytosolic, eag homolog, epididymis luminal protein 12, epididymis luminal protein 9, epididymis secretory protein Li 102, epididymis secretory sperm binding protein Li 53e, erb-b2 receptor tyrosine kinase 1, estrogen receptor related receptor alpha, flavoprotein-linked monooxygenase, glucocorticoid nuclear receptor variant 1, hERG-1, hERR1, hWALp4, heat shock protein family B (small) member 1, mENA, mPGES-1, nr3c1, nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor), orphan nuclear hormone receptor, p21-activated kinase 1, p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast), p42-MAPK, p53 induced apoptosis protein 12, p53 tumor suppressor, p53-induced gene 12 protein, p65-PAK, peptidase nexin-II, pregnane X nuclear receptor variant 2, protein kinase, mitogen-activated, 1, protein kinase, mitogen-activated, 2, protein tyrosine kinase ERK2, sAPP, tumor antigen p55, v-erb-b Avian erythroblastic leukemia viral oncogen homolog, wa2
MW 368.4 Da. High purity flavonoid derivative. Potent antioxidant, anti-inflammatory, analgesic and anticancer agent. Lipooxygenase and cyclooxygenase inhibitor (IC50 values are 8 and 52 μM, respectively). Shows diverse range of actions including free radical scavenging activity, cardio and neuroprotective effects. Blood brain barrier permeable. Active in vitro and in vivo.
458-37-7
Solid
368.4 Da
C21H20O6
969516
Synthetic
Soluble in ethanol to 10 mM. Soluble in DMSO to 10 mM.
Curcumin
High purity flavonoid derivative. Potent antioxidant, anti-inflammatory, analgesic and anticancer agent. Lipooxygenase and cyclooxygenase inhibitor (IC50 values are 8 and 52 μM, respectively). Shows diverse range of actions including free radical scavenging activity, cardio and neuroprotective effects. Blood brain barrier permeable. Active in vitro and in vivo
COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O
COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O
InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+
VFLDPWHFBUODDF-FCXRPNKRSA-N
(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
Ambient - Can Ship with Ice
-20°C
-20°C
Store under desiccating conditions, The product can be stored for up to 12 months
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120618, Curcumin (Diferuloylmethane), Lipooxygenase inhibitor
Anti-c-Jun antibody [E254] - ChIP Grade ab32137 staining c-Jun in HeLa cells treated with curcumin (diferuloylmethane) (ab120618), by ICC/IF. Decrease in c-Jun expression correlates with increased concentration of curcumin (diferuloylmethane) as described in literature.
The cells were incubated at 37°C for 4h in media containing different concentrations of ab120618 (curcumin (diferuloylmethane)) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with Anti-c-Jun antibody [E254] - ChIP Grade ab32137 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com